Indian Pharmaceutical Industry

ICRA RESEARCH SERVICES Indian Pharmaceutical Industry An Update on Emerging Markets – A Key Export Destination Contacts: SubrataICRA Ray RATING FEAT...
Author: Joel Martin
2 downloads 0 Views 753KB Size
ICRA RESEARCH SERVICES

Indian Pharmaceutical Industry An Update on Emerging Markets – A Key Export Destination

Contacts: SubrataICRA Ray RATING FEATURE +91 22 6179 6386 [email protected] Shamsher Dewan +91 124 4545 328 [email protected]

What’s inside? I.

Executive Summary

II.

Snapshot of India’s Pharmaceutical Exports

III.

An update on Emerging Markets with perspective on growth drivers & market potential

IV.

Coverage on Pharmaceutical markets in: a. Brazil i. Market Size, Structure & Growth Drivers ii. Competitive Landscape & Regulatory Developments

b. Russia i. Market Size, Structure & Growth Drivers ii. Competitive Landscape & Regulatory Developments

c. South Africa i. Market Size, Structure & Growth Drivers ii. Competitive Landscape & Regulatory Developments

d. Middle East & North Africa (MENA) e. Asia Pacific – Indonesia, Thailand & Philippine V.

An update on Japan’s evolving generic drug industry

VI.

Impact of regulatory developments & market dynamics

VII.

The Road Ahead…

Annexure I: Snapshot of Indian companies in RoW markets Annexure II: List of ICRA-rated Pharmaceutical Companies

ICRA Limited

P a g e |2

INDIAN PHARMACEUTICAL INDUSTRY An Update on Emerging Markets – A Key Export Destination ICRA RESEARCH SERVICES

Industry Update February 2015

Executive Summary Generic opportunities outweigh challenges emanating across emerging markets

ICRA RATING FEATURE

 With approximately 20% contribution to revenues of leading pharmaceutical companies, Emerging markets have evolved to become an important market segment for Indian pharmaceutical industry. Although United States remains the key growth driver, pharma companies have steadily expanded their presence across some of the key emerging markets.  Aided by acquisitions, geographic expansion and steadily expanding product portfolio, the top-10 pharma companies from India have achieved a CAGR of 23% in revenues from emerging markets over the past five years (i.e. FY 2010-14).  Driven by improving affordability levels, government’s commitment to expanding healthcare access and rising prevalence of lifestyle related disorders, the spending on pharmaceutical products in these markets is estimated to almost double to ~US$380-390 billion by 2017 according to IMS1. Much of this growth is likely to benefit the generic segment which would gain traction on back of government-supported programs and cost competitiveness in markets, which rely heavily on out-of-pocket spending for healthcare.  While the growth prospects in emerging markets remain undisputed, pharma companies also face their fair share of challenges. Frequent regulatory changes, government’s intervention in drug pricing (to contain healthcare costs) and efforts to promote usage of un-branded generics are some of the common themes influencing industry prospects. In some countries, the regulatory framework has also evolved to favour local industry by implementing measures like higher import duties, creating price differentiation and incentives to invest in manufacturing facilities, locally.  The impact of weakening macro-economic environment and political instability across some countries has further added to set of challenges, which has got accentuated by the sharp correction in crude oil prices and its adverse impact on exchange rates of some of the oil-dependent economies like Russia. This is likely to impact margins of companies in the near-term given the intensity of currency de-valuation and limited ability to implement price hikes.  The competitive intensity in emerging markets is also on the rise. While on one hand, local players are moving up the ladder in terms of R&D skills, MNC pharma companies are also increasing their focus on emerging markets in view of single digit growth expectations in mature markets. Besides access to portfolio of innovator drugs, their presence in emerging markets is also characterized by well established marketing network, a factor that is critical for developing a branded generics business. 1

ICRA Limited

IMS Health is a leading global information and technology services company engaged in providing solutions in healthcare industry

P a g e |3

Executive Summary  Despite challenges, Indian pharma companies would however continue to benefit from the growth opportunities that emerging markets offer. With cost competitive manufacturing capabilities and many of the characteristics (i.e. high outof-pocket expenditure on healthcare and preference for branded generics) similar to the Indian market, Indian firms remain in an advantageous position. Additionally, their relatively low market share also provides scope for market traction going forward.  In the following report, we present an update on key emerging markets of Brazil, Russia, South Africa, Middle East & North Africa (MENA), and Asia Pacific from the perspective of industry structure, growth drivers, regulatory landscape and competitive intensity. In each section, we have also commented on the presence of Indian companies in these markets and their strategies going forward.  The report also covers an update on Japan’s generic drug industry, which is going through another phase of government-led mandate to increase generic penetration. With several key drugs also expected to lose patent protection over the near-term, the pro-generic reforms provide adequate opportunities for generic drug manufacturers. At present, Indian companies have relatively limited presence in Japan given the stringent regulatory framework. However, we expect them to increase their focus going forward.  The report concludes with likely strategies that Indian companies would pursue in emerging markets. In our view, acquisitions will play an important role given the long gestation period involved in establishing branded generics business. To address competitive pressures, companies would also shift their focus towards niche therapy areas, biosimilars and segments like OTC that offer greater pricing power. As regulatory framework in some markets supports local manufacturing presence, we expect Indian companies to invest in Greenfield facilities as well in select markets.

ICRA Limited

P a g e |4

ICRA Contact Details

CORPORATE OFFICE Building No. 8, 2nd Floor, Tower A, DLF Cyber City, Phase II, Gurgaon 122002 Ph: +91-124-4545300, 4545800 Fax; +91-124-4545350 REGISTERED OFFICE 1105, Kailash Building, 11th Floor, 26, Kasturba Gandhi Marg, New Delhi – 110 001 Tel: +91-11-23357940-50 Fax: +91-11-23357014 MUMBAI Mr. L. Shivakumar Mobile: 9821086490 3rd Floor, Electric Mansion, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025 Ph : +91-22-30470000, 24331046/53/62/74/86/87 Fax : +91-22-2433 1390 E-mail: [email protected]

GURGAON Mr. Vivek Mathur Mobile: 9871221122 Building No. 8, 2nd Floor, Tower A, DLF Cyber City, Phase II, Gurgaon 122002 Ph: +91-124-4545300, 4545800 Fax; +91-124-4545350 E-mail: [email protected]

ICRA Limited

CHENNAI Mr. Jayanta Chatterjee Mobile: 9845022459 Mr. Leander Rayen Mobile: 9952615551 5th Floor, Karumuttu Centre, 498 Anna Salai, Nandanam, Chennai-600035. Tel: +91-44-45964300, 24340043/9659/8080 Fax:91-44-24343663 E-mail: [email protected] [email protected] KOLKATA Ms. Vinita Baid Mobile: 9007884229 A-10 & 11, 3rd Floor, FMC Fortuna, 234/ 3A, A.J.C. Bose Road, Kolkata-700020. Tel: +91-33-22876617/ 8839, 22800008, 22831411 Fax: +91-33-2287 0728 E-mail: [email protected]

HYDERABAD Mr. M.S.K. Aditya Mobile: 9963253777 301, CONCOURSE, 3rd Floor, No. 7-1-58, Ameerpet, Hyderabad 500 016. Tel: +91-40-23735061, 23737251 Fax: +91-40- 2373 5152 E-mail: [email protected]

AHMEDABAD Mr. Animesh Bhabhalia Mobile: 9824029432 907 & 908 Sakar -II, Ellisbridge, Ahmedabad- 380006 Tel: +91-79-26585049/2008/5494, Fax:+91-79- 2648 4924 E-mail: [email protected]

BANGALORE Mr. Jayanta Chatterjee Mobile: 9845022459 'The Millenia', Tower B, Unit No. 1004, 10th Floor, Level 2, 12-14, 1 & 2, Murphy Road, Bangalore - 560 008 Tel: +91-80-43326400, Fax: +91-80-43326409 E-mail: [email protected]

PUNE Mr. L. Shivakumar Mobile: 9821086490 5A, 5th Floor, Symphony, S. No. 210, CTS 3202, Range Hills Road, Shivajinagar, Pune-411 020 Tel : +91- 20- 25561194, 25560195/196, Fax : +91- 20- 2553 9231 E-mail: [email protected]

P a g e |5

ICRA Limited CORPORATE OFFICE Building No. 8, 2nd Floor, Tower A; DLF Cyber City, Phase II; Gurgaon 122 002 Tel: +91 124 4545300; Fax: +91 124 4545350 Email: [email protected], Website: www.icra.in REGISTERED OFFICE 1105, Kailash Building, 11 Floor; 26 Kasturba Gandhi Marg; New Delhi 110001 Tel: +91 11 23357940-50; Fax: +91 11 23357014 th

Branches: Mumbai: Tel.: + (91 22) 24331046/53/62/74/86/87, Fax: + (91 22) 2433 1390 Chennai: Tel + (91 44) 2434 0043/9659/8080, 2433 0724/ 3293/3294, Fax + (91 44) 2434 3663 Kolkata: Tel + (91 33) 2287 8839 /2287 6617/ 2283 1411/ 2280 0008, Fax + (91 33) 2287 0728 Bangalore: Tel + (91 80) 2559 7401/4049 Fax + (91 80) 559 4065 Ahmedabad: Tel + (91 79) 2658 4924/5049/2008, Fax + (91 79) 2658 4924 Hyderabad: Tel +(91 40) 2373 5061/7251, Fax + (91 40) 2373 5152 Pune: Tel + (91 20) 2552 0194/95/96, Fax + (91 20) 553 9231 © Copyright, 2015 ICRA Limited. All Rights Reserved. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable. Although reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies, while publishing or otherwise disseminating other reports may have presented data, analyses and/or opinions that may be inconsistent with the data, analyses and/or opinions in this publication. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.

ICRA Limited

P a g e |6

Suggest Documents